摘要
The prognosis of metastatic disease of esophagogastric junction adenocarcinoma remains poor,despite using a variety of regimens using cytotoxic agents.Recent understanding of molecular characteristic and tumor microenvironment of this cancer is currently instigating new therapeutic options.In this review,we summarized previous evidences of cytotoxic agents widely used worldwide,and updated recent developments of molecular targeted drugs,and immune checkpoint inhibitors.
